• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    838.20 -84.59 (-9.17%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
    Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
    Via Benzinga
    Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
    Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
    Via Benzinga
    Regeneron Earnings Top Views For Biotech Giant
    Shares of the biotech giant have been in a sharp slide. 
    Via Investor's Business Daily
    $100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
    Via Benzinga
    A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
    Via Benzinga
    Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
    Via Benzinga
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
    Via Benzinga
    EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
    EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
    Via Benzinga
    Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
    One of these players has split its stock in the past. The other one hasn't. 
    Via The Motley Fool
    Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
    Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
    Via Benzinga
    Market Whales and Their Recent Bets on REGN Options
    Via Benzinga
    What the Options Market Tells Us About Regeneron Pharmaceuticals
    Via Benzinga
    Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
    Via Benzinga
    Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
    There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
    Via Talk Markets
    Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
    Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
    Via Talk Markets
    Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
    Via Benzinga
    Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
    The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
    Via Benzinga
    A Closer Look at 24 Analyst Recommendations For Regeneron Pharmaceuticals
    Via Benzinga
    Market Whales and Their Recent Bets on REGN Options
    Via Benzinga
    Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
    Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects... 
    Via Benzinga
    Should You Buy the Dip on This Top Growth Stock?
    The biotech needs to overcome an issue most drugmakers face at some point. 
    Via The Motley Fool
    (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
    Via Benzinga
    $100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
    Via Benzinga
    Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
    10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
    Via Benzinga
    A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
    Via Benzinga
    Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
    The S&P 500 hit record highs, fueled by Micron and Chinese stimulus. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
    The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
    Via Benzinga
    Exposures Product Safety
    Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
    The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
    Via Investor's Business Daily
    Exposures Product Safety
    Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
    Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.